First Person Dosed in Novel Gene Editing Clinical Trial
First Person Dosed in Novel Gene Editing Clinical Trial
The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.
The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.
hypercholesterolemia
Infographic: Piecing the Cholesterol Puzzle
Diana Kwon | Apr 30, 2018 | 1 min read
How a rare disease led to an understanding of the basics of cholesterol regulation.
Exome Study Reveals Novel Disease-Linked Alleles
Anna Azvolinsky | Dec 22, 2016 | 4 min read
By combining whole-exome sequencing data with longitudinal electronic health record information for 50,000 individuals, researchers have identified novel disease associations.
Putting the Pee in Pluripotency
Kerry Grens | Apr 1, 2016 | 4 min read
One man’s waste is another man’s treasure trove of stem cells.